PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.345 AUD -5.28% Market Closed
Market Cap: 784.5m AUD

Net Margin
PYC Therapeutics Ltd

-182.4%
Current
-148%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-182.4%
=
Net Income
-48.2m
/
Revenue
26.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
PYC Therapeutics Ltd
ASX:PYC
784.5m AUD
-182%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.6B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
165.5B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.9B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
128.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.3B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

PYC Therapeutics Ltd
Glance View

Market Cap
784.5m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
0.663 AUD
Overvaluation 51%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-182.4%
=
Net Income
-48.2m
/
Revenue
26.4m
What is the Net Margin of PYC Therapeutics Ltd?

Based on PYC Therapeutics Ltd's most recent financial statements, the company has Net Margin of -182.4%.

Back to Top